Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pediatric Endocrinology

Building Your Care Team and Starting Treatment

At a Glance

Treatment for CMO II deficiency usually combines fludrocortisone to replace the missing hormone with carefully prescribed salt, regular blood tests and growth checks, and a written plan for vomiting or diarrhea to prevent dehydration.

Treating CMO II deficiency focuses on one goal: replacing what is missing so your child’s body can maintain its balance [1]. Because this is an “isolated” deficiency—meaning only aldosterone is affected—treatment is typically more straightforward than other adrenal conditions [2][3]. With consistent care, most children see rapid improvements in their growth and energy [4][5].

The Standard of Care

The medical management for CMO II involves two main components that work together to stabilize your child’s salt levels [6].

  • Fludrocortisone: This is a mineralocorticoid medication that acts as a stand-in for the missing aldosterone [6][7]. It tells the kidneys to stop “wasting” salt and to keep it in the bloodstream [1]. It is usually given once or twice daily as a liquid or a small tablet [4].
  • Salt Supplementation: Especially in infancy, children with CMO II often need more salt than they can get from breast milk or formula alone [6][8]. Your doctor may prescribe a specific amount of sodium chloride (salt) solution to be added to their bottles [6].

Important Medication Safety Rules: Never improvise the salt dose or use ad hoc table salt. A mixing error or unsupervised increase in sodium can cause dangerous fluid retention, high blood pressure, or seizures. Only use the specific concentration of liquid sodium chloride prescribed by your doctor, and always measure it accurately using a medical oral syringe. Never change the fludrocortisone or salt dose independently. If your child vomits a dose, refer to your written sick-day plan or call your endocrinologist for instructions on whether to re-dose.

Goals of Treatment

When treatment is working correctly, you should see three major changes:

  1. Electrolyte Balance: Sodium and potassium levels in the blood will move into the normal range [5].
  2. Renin Control: The level of renin (the “signal” hormone) may decrease, showing that the body no longer feels it is “starving” for salt [9][2]. Clinicians do not just aim to lower renin; they interpret it alongside the child’s blood pressure, electrolytes, growth, and treatment status.
  3. Catch-Up Growth: This is often the most visible sign of success. In one study, infants with this condition began to grow at a normal rate within a median of just two months after starting treatment, though timelines vary widely [4].

Just as too little medication is dangerous, too much fludrocortisone or salt can lead to over-replacement. Contact your doctor if you notice high blood pressure (hypertension), unusual swelling (edema), rapid weight gain, headaches, or if labs show low potassium (hypokalemia).

Managing Illness and “Sick Days”

Because children with confirmed, isolated CMO II usually have normal cortisol (the stress hormone), they typically do not need “stress-dose” steroids during common illnesses like a cold or ear infection [1][3].

However, the risk of dehydration remains high during any illness that involves vomiting or diarrhea [10][6]. If your child cannot keep their medication or salt down, they may need IV fluids in a hospital setting to prevent a salt-wasting crisis [10]. Your endocrinologist will provide a “Sick Day Plan” that outlines when to increase fluids and when to head to the emergency room [11]. If ER clinicians ever suspect an adrenal crisis in your child, never refuse empiric emergency steroids based on this guide.

Building Your Care Team

Managing a rare condition requires a team of experts who communicate with each other. Your team should include:

  • Pediatric Endocrinologist: This is the lead specialist who will manage the hormone replacement and monitor lab work [12][4].
  • Pediatrician: They will handle routine care, vaccinations, and general illnesses, working closely with the endocrinologist [12].
  • Pediatric Dietitian: They can help ensure your child is getting enough sodium and calories, especially as you transition to solid foods [1].

Vetting Your Specialist

Since CMO II is rare, it is okay to ask your pediatric endocrinologist about their experience. You might ask:

  • “How many children with isolated aldosterone synthase deficiency have you treated?”
  • “Are you comfortable distinguishing this from CAH (Congenital Adrenal Hyperplasia) to ensure my child isn’t over-treated with steroids?”
  • “How often will we need to see you for monitoring during the first year of my child’s life?”

As children get older, their bodies often become more efficient at keeping salt [4]. Some children are eventually able to reduce or even stop their medication under strict supervision, though long-term monitoring by an endocrinologist is always recommended [4][5].

Common questions in this guide

What medicines are used to treat CMO II deficiency?
CMO II deficiency is usually treated with fludrocortisone, a medicine that acts like the missing aldosterone. Infants and some children also need a prescribed sodium chloride solution to replace salt lost by the kidneys.
Why does my child need extra salt with CMO II deficiency?
The condition can make the kidneys waste salt, and breast milk or formula may not provide enough sodium, especially in infancy. Use only the concentration and amount prescribed by your child’s doctor; ordinary table salt should not be substituted.
What should I do if my child with CMO II deficiency vomits or has diarrhea?
Although confirmed isolated CMO II deficiency usually does not require extra steroid doses for a routine cold, vomiting and diarrhea can cause dangerous dehydration. Follow your written sick-day plan and contact the endocrinology team; if your child cannot keep medicine or salt down, urgent evaluation and intravenous fluids may be needed.
How will doctors know whether CMO II treatment is working?
Doctors monitor blood sodium and potassium, renin, blood pressure, and growth. They interpret these measures together because lowering renin alone is not the only goal of treatment.
What are signs that my child is receiving too much fludrocortisone or salt?
Contact the doctor about high blood pressure, unusual swelling, rapid weight gain, headaches, or low potassium on blood tests. Do not increase, reduce, or stop fludrocortisone or salt without medical instructions.
Who should be part of my child’s CMO II care team?
A pediatric endocrinologist typically leads hormone replacement and laboratory monitoring, while the pediatrician manages routine care and illnesses. A pediatric dietitian can help with sodium and calorie needs, especially as your child begins eating solid foods.
Can children with CMO II deficiency eventually reduce or stop treatment?
Some children become better able to retain salt as they grow and may be able to reduce or stop medication. Any change must be made gradually and under an endocrinologist’s supervision with continued monitoring.

Get notified when new evidence is published on corticosterone methyloxidase type 2 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Clinical and Genetic Characteristics of Patients with Corticosterone Methyloxidase Deficiency Type 2: Novel Mutations in CYP11B2

    Turan H, Dağdeviren Çakır A, Özer Y, et al.

    Journal of clinical research in pediatric endocrinology 2021; (13(2)):232-238 doi:10.4274/jcrpe.galenos.2020.2019.0216.

    PMID: 32539318
  2. 2

    Congenital aldosterone deficiency and its resistance.

    Tajima T, Amano N, Ishii T, et al.

    Endocrine journal 2026; (73(6)):751-763 doi:10.1507/endocrj.EJ25-0630.

    PMID: 41905953
  3. 3

    Severe Aldosterone Synthase Deficiency in a 9-Day-Old Lebanese Boy: The Importance of Functional Studies to Establish Pathogenicity of Seemingly Benign Variants in CYP11B2.

    Ghaddhab C, Capper CP, Larrivée-Vanier S, et al.

    Hormone research in paediatrics 2025; (98(1)):96-102 doi:10.1159/000536437.

    PMID: 38316111
  4. 4

    Catch-up Growth and Discontinuation of Fludrocortisone Treatment in Aldosterone Synthase Deficiency.

    Gurpinar Tosun B, Kendir Demirkol Y, Seven Menevse T, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(1)):e106-e117 doi:10.1210/clinem/dgab619.

    PMID: 34415991
  5. 5

    Analysis of novel heterozygous mutations in the CYP11B2 gene causing congenital aldosterone synthase deficiency and literature review.

    Miao H, Yu Z, Lu L, et al.

    Steroids 2019; (150()):108448 doi:10.1016/j.steroids.2019.108448.

    PMID: 31302112
  6. 6

    Neonatal salt wasting syndrome: Aldosterone synthase deficiency caused by a new splicing variant in CYP11B2.

    Gerard R, Sauvestre C, Barat P, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2024; (31(2)):157-160 doi:10.1016/j.arcped.2023.10.007.

    PMID: 38262861
  7. 7

    Cracking the code of aldosterone synthase deficiency: bridging genetics and biochemistry: a case report.

    Kamarajan LP, Mahto M, Kumar S, Kumar P

    Laboratory medicine 2025; (56(4)):419-422 doi:10.1093/labmed/lmae102.

    PMID: 39700478
  8. 8

    Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism.

    Martín-Rivada Á, Argente J, Martos-Moreno GÁ

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(11)):1501-1505.

    PMID: 32809961
  9. 9

    A novel compound heterozygous mutation in CYP11B2 (p.A153P and p.Q337*) associated with primary hypoaldosteronism.

    Yang J, Li L, Sun Y, et al.

    Frontiers in medicine 2026; (13()):1740124 doi:10.3389/fmed.2026.1740124.

    PMID: 41889508
  10. 10

    Congenital primary adrenal insufficiency and selective aldosterone defects presenting as salt-wasting in infancy: a single center 10-year experience.

    Bizzarri C, Olivini N, Pedicelli S, et al.

    Italian journal of pediatrics 2016; (42(1)):73 doi:10.1186/s13052-016-0282-3.

    PMID: 27485500
  11. 11

    SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook.

    Reznik Y, Barat P, Bertherat J, et al.

    Annales d'endocrinologie 2018; (79(1)):1-22 doi:10.1016/j.ando.2017.12.001.

    PMID: 29338844
  12. 12

    Congenital hyperreninemic hypoaldosteronism due to aldosterone synthase deficiency type I in a Portuguese patient - Case report and review of literature.

    Lages AS, Vale B, Oliveira P, et al.

    Archives of endocrinology and metabolism 2019; (63(1)):84-88 doi:10.20945/2359-3997000000107.

    PMID: 30864636

This page provides educational information about treating CMO II deficiency in children and is not a substitute for medical advice. Your child’s pediatric endocrinologist should set every fludrocortisone, salt, and sick-day instruction for your child.